Edition:
United Kingdom

AnaptysBio Inc (ANAB.OQ)

ANAB.OQ on NASDAQ Stock Exchange Global Select Market

71.38USD
12 Dec 2018
Change (% chg)

$-0.31 (-0.43%)
Prev Close
$71.69
Open
$71.98
Day's High
$73.00
Day's Low
$70.52
Volume
127,749
Avg. Vol
140,221
52-wk High
$134.00
52-wk Low
$62.90

Latest Key Developments (Source: Significant Developments)

Anaptysbio Announces Pricing Of Public Offering Of Common Stock
Wednesday, 26 Sep 2018 

Sept 25 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.20 MILLION COMMON SHARES PRICED AT $94.46 PER SHARE.  Full Article

Anaptysbio Announces Proposed Public Offering Of Common Stock
Monday, 24 Sep 2018 

Sept 24 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ANAPTYSBIO INC - INTENDS TO OFFER $200 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.ANAPTYSBIO INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND RESEARCH AND DEVELOPMENT ACTIVITIES FOR ITS CLINICAL DEVELOPMENT PROGRAMS.  Full Article

Anaptysbio Qtrly Loss Per Share $0.63
Tuesday, 8 May 2018 

May 8 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES.ANAPTYSBIO INC - TOP-LINE PHASE 2A DATA FROM ANB020 IN EOSINOPHILIC ASTHMA EXPECTED IN Q3 OF 2018.ANAPTYSBIO INC - EXPECTS THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND ITS CURRENT OPERATING PLAN THROUGH END OF 2019.ANAPTYSBIO INC QTRLY LOSS PER SHARE $0.63.  Full Article

Anaptysbio qtrly loss per share $0.45‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Anaptysbio Inc ::Anaptysbio announces third quarter 2017 financial results and provides pipeline updates.Qtrly loss per share $0.45‍​.Q3 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Anaptysbio Inc :Anaptysbio reports positive anb019 top-line phase 1 clinical trial results.Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties in study​.ANB019 was well-tolerated by all subjects and no dose-limiting toxicities were observed to date in study​.Plans to initiate phase 2 clinical trials of ANB019 in generalized pustular psoriasis, palmo-plantar pustular psoriasis patients in 2018​.  Full Article

Cormorant Asset Management reports 5.02 pct passive stake in Anaptysbio as of Oct. 19 ‍​
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Cormorant Asset Management LLC: :Cormorant Asset Management, LLC reports 5.02 percent passive stake in Anaptysbio Inc as of October 19 - SEC filing ‍​.  Full Article

AnaptysBio prices public offering of 3 mln shares at $68.50 per share
Friday, 13 Oct 2017 

Oct 12 (Reuters) - AnaptysBio Inc -:AnaptysBio announces pricing of public offering.Says public offering of 3.00 million common shares priced at $68.50per share.  Full Article

Anaptysbio files for offering of 3 million shares
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Anaptysbio Inc :Anaptysbio files for offering of 3 million shares for up to $121.1 million – sec filing .  Full Article

AnaptysBio reports positive data from phase 2A clinical trial of ANB020 in atopic dermatitis
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - AnaptysBio Inc : :AnaptysBio reports positive topline proof-of-concept data from phase 2A clinical trial of ANB020 in atopic dermatitis.AnaptysBio Inc - ‍83 percent of patients achieved EASI-50 at day 29 following a single dose of ANB020​.AnaptysBio Inc - ‍ANB020 was generally well tolerated in all patients as of this interim analysis​.AnaptysBio-Continues to advance its ongoing ANB020 phase 2A studies in adults with severe peanut allergy with topline data expected in Q4 of 2017​.Anaptysbio Inc - ‍during first half of 2018, co plans to initiate a phase 2B randomized, double-blinded, placebo-controlled study​.AnaptysBio Inc - no severe adverse events have been reported to date on ‍ANB020 ​.AnaptysBio- also continues to advance ongoing ANB020 phase 2A studies in adults with severe eosinophilic asthma, topline data expected in first half of 2018​.  Full Article

Frazier Healthcare V, L.P reports 18.5 pct stake in Anaptysbio as of Jan. 31, 2017 - SEC filing
Friday, 10 Feb 2017 

Anaptysbio Inc :Frazier Healthcare V, L.P reports 18.5 percent stake in Anaptysbio Inc as of January 31, 2017 - SEC filing.  Full Article